#1 Clinical Trials Search in Europe

[11C]Az14193391

This article discusses the ongoing clinical trials of [11C]Az14193391, a promising new drug being investigated for various advanced solid tumors. The trials aim to assess the safety, tolerability, and effectiveness of this compound, both as a standalone treatment and in combination with other anti-cancer agents. The studies focus on patients with specific genetic mutations and various types of cancer, including breast, ovarian, pancreatic, and prostate cancers.

Table of Contents

What is [11C]AZ14193391?

[11C]AZ14193391 is an investigational drug being developed by AstraZeneca for the treatment of various advanced solid tumors[1]. It is currently being studied in clinical trials to evaluate its safety, effectiveness, and how it works in the body. The “[11C]” in the name indicates that the drug is labeled with a radioactive form of carbon, which allows researchers to track its movement and activity in the body using special imaging techniques.

How is [11C]AZ14193391 administered?

[11C]AZ14193391 is given as a solution for injection through an intravenous bolus, which means it is injected directly into a vein as a single, quick dose[1]. This method of administration allows the drug to quickly enter the bloodstream and reach its target sites in the body.

What types of cancer is [11C]AZ14193391 being studied for?

The clinical trial is investigating [11C]AZ14193391 for several types of advanced solid tumors, including:

  • Ovarian cancer
  • Breast cancer
  • Pancreatic cancer
  • Prostate cancer
  • Glioma (a type of brain tumor)
  • Non-small cell lung cancer (NSCLC)
  • Endometrial cancer

The study is particularly focused on patients with specific genetic mutations, such as BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, which are associated with an increased risk of certain cancers[1].

How does [11C]AZ14193391 work?

While the exact mechanism of action is not fully described in the provided information, [11C]AZ14193391 appears to be related to a class of drugs that target PARP1 (Poly (ADP-ribose) polymerase 1). PARP1 is an enzyme involved in DNA repair, and inhibiting it can be effective in treating certain types of cancers, especially those with specific genetic mutations[1].

The study aims to assess the drug’s ability to occupy PARP1 in the brain, which suggests it may be designed to cross the blood-brain barrier and potentially treat brain tumors or brain metastases[1].

What is the current stage of research for [11C]AZ14193391?

[11C]AZ14193391 is currently in a Phase I/IIa clinical trial, which is considered an early stage of research[1]. This type of study is designed to:

  1. Evaluate the safety and tolerability of the drug
  2. Determine the appropriate dosage
  3. Assess how the drug behaves in the body (pharmacokinetics)
  4. Explore potential biological activity and anti-tumor effects

The study is divided into several modules, each focusing on different aspects of the drug’s performance, either alone or in combination with other cancer treatments[1].

Who may be eligible to participate in clinical trials?

Eligibility criteria for the clinical trial include:

  • Age 18 years or older
  • Diagnosed with an advanced solid tumor that has progressed
  • Adequate organ and bone marrow function
  • Life expectancy of at least 12 weeks
  • For some modules, specific genetic mutations or cancer types

There are also several exclusion criteria, such as certain medical conditions or prior treatments, that may prevent participation[1].

What are the potential benefits and risks?

As an early-stage clinical trial, the potential benefits and risks of [11C]AZ14193391 are not yet fully known. However, participants may benefit from:

  • Access to a new potential treatment for advanced cancer
  • Close monitoring by medical professionals
  • Contributing to the advancement of cancer research

Potential risks may include:

  • Unknown side effects
  • The possibility that the treatment may not be effective
  • Time commitment for study-related procedures and visits

The study is designed to carefully monitor participants for any adverse effects and to evaluate the drug’s safety profile[1].

Aspect Details
Drug Name [11C]Az14193391
Administration Intravenous injection
Cancer Types Studied Breast, ovarian, pancreatic, prostate, glioma, and other advanced solid tumors
Study Phases Phase I/IIa
Main Objectives Assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy
Genetic Factors Focus on mutations in BRCA1, BRCA2, PALB2, RAD51C, RAD51D
Combination Therapies Temozolomide, Trastuzumab deruxtecan, Datopotamab deruxtecan
Key Assessments Adverse events, dose-limiting toxicities, maximum tolerated dose, tumor response (RECIST criteria)

FAQ

  • What is [11C]Az14193391? [11C]Az14193391 is an investigational drug being studied for its potential in treating various advanced solid tumors. It is currently undergoing clinical trials to determine its safety, effectiveness, and optimal dosing.
  • What types of cancer are being studied with [11C]Az14193391? The clinical trials are focusing on several types of advanced cancers, including breast, ovarian, pancreatic, prostate, and glioma (a type of brain tumor). Some trials are specifically looking at cancers with certain genetic mutations.
  • How is [11C]Az14193391 administered? [11C]Az14193391 is administered as a solution for injection, typically given intravenously (directly into the bloodstream).
  • Are there any specific genetic factors considered in these trials? Yes, some parts of the study focus on patients with specific genetic mutations, such as BRCA1, BRCA2, PALB2, RAD51C, or RAD51D mutations. These genetic factors may influence how patients respond to the treatment.
  • What are the main objectives of these clinical trials? The primary objectives are to assess the safety and tolerability of [11C]Az14193391, determine its appropriate dosing, and evaluate its effectiveness in treating various types of advanced cancers. The trials also aim to understand how the drug interacts with other anti-cancer treatments.

Ongoing Clinical Trials on [11C]Az14193391

  • Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

    Recruiting

    2 1 1 1
    Investigated drugs:
    Spain Sweden

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Biomarker: A measurable indicator of a biological condition or state, often used to determine the presence or progress of a disease or the effects of treatment.
  • Monotherapy: Treatment using a single drug.

References

  1. http://clinicaltrials.eu/trial/study-of-azd9574-and-temozolomide-for-patients-with-advanced-solid-tumors-including-breast-ovarian-pancreatic-and-prostate-cancers/